Skip to main content
. Author manuscript; available in PMC: 2016 Nov 9.
Published in final edited form as: Clin Exp Neuroimmunol. 2014 Apr 22;5(3):290–303. doi: 10.1111/cen3.12107

Table 2.

Metrics from six classes of aquaporin-4 antibody assays

NMO Patients Sensitivity
Mean (95% CI)
Range MS Patients Specificity
Mean (95% CI)
Range Likelihood
Ratios§






Assay Studies Tested Pos Min Max Tested Pos Min Max Accuracy LR+ LR−
CBA 9 266 204 76.7 (71.6–81.8) 55.6 96.7 531 1 99.8 (99.4–100.2) 87.5 100 76.5 383.5 0.23
FACS 3 89 56 62.9 (52.9–73.0) 51.7 71.4 235 2 99.1 (98.0–100.3) 82.4 100 62.3 69.9 0.37
ELISA 5 139 89 64.0 (56.1–72.0) 48.3 71.9 203 7 96.6 (94.0–99.1) 85.9 100 61.8 18.8 0.37
IIF 15 446 280 62.8 (58.3–67.3) 40.0 95.0 1018 26 97.4 (96.5–98.4) 87.5 100 61.2 24.2 0.38
RIPA 1 37 21 56.8 (40.8–72.7) 144 4 97.2 (94.5–99.9) 55.2 20.3 0.44
FIPA 4 152 74 48.7 (40.7–56.6) 32.5 76.0 397 2 99.5 (98.8–100.2) 97.4 100 48.5 97.4 0.52

The lowest and highest mean sensitivity/specificity from individual studies in each method category.

Accuracy = (mean sensitivity × mean specificity)/100.

§

Likelihood ratio (LR)+ = sensitivity/(1-specificity), LR− = (1-sensitivity)/specificity.

Ninety-five percentage confidence interval for sensitivity (or specificity) = √((1-sensitivity) × sensitivity/number of tests) × 1.96.

CBA, cell-based assay; ELISA, enzyme-linked immunosorbent assay; FACS, flow cytometry; FlPA, fluorescence immunoprecipitation assay; IIF, indirect immunofluorescence; MS, multiple sclerosis; NMO, neuromyelitis optica; RlPA, radioimmunoprecipitation assay.